Last reviewed · How we verify

NCT04952883

Hydrogen Sulfide and Pulmonary Vascular Remodeling on HRCT in Patients With COPD

Completed Last updated 12 July 2021
What this trial tests

trial in Chronic Obstructive Pulmonary Disease in 100 participants. Completed in 1 December 2017.

Timeline
1 December 2016
Primary endpoint
1 September 2017
1 December 2017

Quick facts

Lead sponsorPeking University Third Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 December 2016
Primary completion1 September 2017
Estimated completion1 December 2017
Sites1 location across China

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Eligibility, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HRCT was used to evaluate pulmonary vascular remodeling in COPD. The role of H2S in pulmonary vascular remodeling in COPD was analyzed, in order to provide a basis for seeking new therapeutic targets.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Recent Advances in Molecular Research on Hydrogen Sulfide (H<sub>2</sub>S) Role in Diabetes Mellitus (DM)-A Systematic Review.
    Munteanu C, Rotariu M, Turnea M, Dogaru G, et al · · 2022 · cited 23× · PMID 35743160 · DOI 10.3390/ijms23126720

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04952883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing